Antivascular	0	12	B-Multi-tissue_structure
actions	13	20	O
of	21	23	O
microtubule	24	35	B-Drug_or_compound
-	35	36	I-Drug_or_compound
binding	36	43	I-Drug_or_compound
drugs	44	49	I-Drug_or_compound
.	49	50	O

Microtubule	52	63	B-Drug_or_compound
-	63	64	I-Drug_or_compound
binding	64	71	I-Drug_or_compound
drugs	72	77	I-Drug_or_compound
(	78	79	O
MBD	79	82	B-Drug_or_compound
)	82	83	O
are	84	87	O
widely	88	94	O
used	95	99	O
in	100	102	O
cancer	103	109	B-Pathological_formation
chemotherapy	110	122	O
and	123	126	O
also	127	131	O
have	132	136	O
clinically	137	147	O
relevant	148	156	O
antiangiogenic	157	171	O
and	172	175	O
vascular	176	184	B-Multi-tissue_structure
-	184	185	O
disrupting	185	195	O
properties	196	206	O
.	206	207	O

These	208	213	O
antivascular	214	226	B-Multi-tissue_structure
actions	227	234	O
are	235	238	O
due	239	242	O
in	243	245	O
part	246	250	O
to	251	253	O
direct	254	260	O
effects	261	268	O
on	269	271	O
endothelial	272	283	B-Cell
cells	284	289	I-Cell
,	289	290	O
and	291	294	O
all	295	298	O
MBDs	299	303	B-Drug_or_compound
(	304	305	O
both	305	309	O
microtubule	310	321	B-Cellular_component
-	321	322	O
stabilizing	322	333	O
and	334	337	O
microtubule	338	349	B-Cellular_component
-	349	350	O
destabilizing	350	363	O
)	363	364	O
inhibit	365	372	O
endothelial	373	384	B-Cell
cell	385	389	I-Cell
proliferation	390	403	O
,	403	404	O
migration	405	414	O
,	414	415	O
and	416	419	O
tube	420	424	B-Tissue
formation	425	434	O
in	435	437	O
vitro	438	443	O
,	443	444	O
actions	445	452	O
that	453	457	O
are	458	461	O
thought	462	469	O
to	470	472	O
correspond	473	483	O
to	484	486	O
therapeutic	487	498	O
antiangiogenic	499	513	O
actions	514	521	O
.	521	522	O

In	523	525	O
addition	526	534	O
,	534	535	O
the	536	539	O
microtubule	540	551	B-Drug_or_compound
-	551	552	I-Drug_or_compound
destabilizing	552	565	I-Drug_or_compound
agents	566	572	I-Drug_or_compound
cause	573	578	O
prominent	579	588	O
changes	589	596	O
in	597	599	O
endothelial	600	611	B-Cell
cell	612	616	I-Cell
morphology	617	627	O
,	627	628	O
an	629	631	O
action	632	638	O
associated	639	649	O
with	650	654	O
rapid	655	660	O
vascular	661	669	B-Multi-tissue_structure
collapse	670	678	O
in	679	681	O
vivo	682	686	O
.	686	687	O

The	688	691	O
effects	692	699	O
on	700	702	O
endothelial	703	714	B-Cell
cells	715	720	I-Cell
occur	721	726	O
in	727	729	O
vitro	730	735	O
at	736	738	O
low	739	742	O
drug	743	747	O
concentrations	748	762	O
,	762	763	O
which	764	769	O
do	770	772	O
not	773	776	O
affect	777	783	O
microtubule	784	795	B-Cellular_component
gross	796	801	O
morphology	802	812	O
,	812	813	O
do	814	816	O
not	817	820	O
cause	821	826	O
microtubule	827	838	B-Cellular_component
bundling	839	847	O
or	848	850	O
microtubule	851	862	B-Cellular_component
loss	863	867	O
and	868	871	O
do	872	874	O
not	875	878	O
induce	879	885	O
cell	886	890	B-Cell
cycle	891	896	O
arrest	897	903	O
,	903	904	O
apoptosis	905	914	O
,	914	915	O
or	916	918	O
cell	919	923	B-Cell
death	924	929	O
.	929	930	O

Rather	931	937	O
,	937	938	O
it	939	941	O
has	942	945	O
been	946	950	O
hypothesized	951	963	O
that	964	968	O
,	968	969	O
at	970	972	O
low	973	976	O
concentrations	977	991	O
,	991	992	O
MBDs	993	997	B-Drug_or_compound
produce	998	1005	O
more	1006	1010	O
subtle	1011	1017	O
effects	1018	1025	O
on	1026	1028	O
microtubule	1029	1040	B-Cellular_component
dynamics	1041	1049	O
,	1049	1050	O
block	1051	1056	O
critical	1057	1065	O
cell	1066	1070	B-Cell
signaling	1071	1080	O
pathways	1081	1089	O
,	1089	1090	O
and	1091	1094	O
prevent	1095	1102	O
the	1103	1106	O
microtubules	1107	1119	B-Cellular_component
from	1120	1124	O
properly	1125	1133	O
interacting	1134	1145	O
with	1146	1150	O
transient	1151	1160	O
subcellular	1161	1172	B-Cellular_component
assemblies	1173	1183	I-Cellular_component
(	1184	1185	O
focal	1185	1190	B-Cellular_component
adhesions	1191	1200	I-Cellular_component
and	1201	1204	O
adherens	1205	1213	B-Cellular_component
junctions	1214	1223	I-Cellular_component
)	1223	1224	O
whose	1225	1230	O
subsequent	1231	1241	O
stabilization	1242	1255	O
and	1256	1259	O
/	1259	1260	O
or	1260	1262	O
maturation	1263	1273	O
are	1274	1277	O
required	1278	1286	O
for	1287	1290	O
cell	1291	1295	B-Cell
motility	1296	1304	O
and	1305	1308	O
cell	1309	1313	B-Cell
-	1313	1314	O
cell	1314	1318	B-Cell
interactions	1319	1331	O
.	1331	1332	O

This	1333	1337	O
review	1338	1344	O
will	1345	1349	O
focus	1350	1355	O
on	1356	1358	O
recent	1359	1365	O
studies	1366	1373	O
to	1374	1376	O
define	1377	1383	O
the	1384	1387	O
molecular	1388	1397	O
mechanisms	1398	1408	O
for	1409	1412	O
the	1413	1416	O
antivascular	1417	1429	B-Multi-tissue_structure
actions	1430	1437	O
of	1438	1440	O
the	1441	1444	O
MBDs	1445	1449	B-Drug_or_compound
,	1449	1450	O
information	1451	1462	O
that	1463	1467	O
could	1468	1473	O
be	1474	1476	O
useful	1477	1483	O
in	1484	1486	O
the	1487	1490	O
identification	1491	1505	O
or	1506	1508	O
design	1509	1515	O
of	1516	1518	O
agents	1519	1525	O
whose	1526	1531	O
actions	1532	1539	O
more	1540	1544	O
selectively	1545	1556	O
target	1557	1563	O
the	1564	1567	O
tumor	1568	1573	B-Multi-tissue_structure
vasculature	1574	1585	I-Multi-tissue_structure
.	1585	1586	O

